Our vision is to fundamentally transform prenatal diagnostics by making cell-free non-invasive prenatal testing (cfNIPT), chorionic villus sampling (CVS) and amniocentesis (Amnio) obsolete.
Our vision is to fundamentally transform prenatal diagnostics by making cell-free non-invasive prenatal testing (cfNIPT), chorionic villus sampling (CVS) and amniocentesis (Amnio) obsolete.
If you are pregnant
ARCEDI’s prenatal tests can give you peace of mind concerning your future child. Learn more about EVITA TEST COMPLETE and EVITA TEST GENDER at evitatest.com
TECHNOLOGY
ARCEDI’s unique technology isolates fetal cells from maternal blood and uses them for genetic analysis
PRODUCT
With ‘EVITA TEST COMPLETE’ ARCEDI is the first company to provide genome-wide analysis of the fetus using circulating fetal cells
PATENTS
ARCEDI’s strong IP portfolio covers four patents and provides global protection through 2031
Latest news
Diagnosis of hydatidiform moles using circulating gestational trophoblasts isolated from maternal blood
Introduction: Identifying hydatidiform moles (HMs) is crucial due to the risk of gestationaltrophoblastic neoplasia. When a HM is suspected on clinical findings, surgical termination isrecommended.
Noninvasive prenatal screening for cystic fibrosis using circulating trophoblasts: Detection of the 50 most common disease‐causing variants
Objectives: Cystic fibrosis (CF) is one of the most common severe autosomal recessive disorders. Prenatal or preconception CF screening is offered in some countries. A
Remembering Steen
We pay tribute to Prof. Steen Kølvraa, one of the founders of ARCEDI Bitoech, and a pioneer in the fetal cell research in Denmark, who passed away six years ago on 31st March 2016.
Newsletter
Subscribe to our newsletter to get the latest updates on products and new scientific publications on ARCEDI technology.
